 |
adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine |
|---|---|
| Trade Name | |
| Orphan Indication | Intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity) |
| USA Market Approval | USA |
| USA Designation Date | 2015-06-08 00:00:00 |
| Sponsor | PNP Therapeutics, Inc.;15 Richard Arrington Jr. Blvd North;Birmingham, Alabama, 35203 |
